In my next episode of The Morale Monologue, I’m going to be introducing everybody to Envisagenics, and their new drug discovery platform they call SpliceCore. This discovery platform is nothing more than a huge database of information pertaining to RNA. RNA is an acronym that stands for ribonucleic acid. In layman’s terms, RNA is the in between molecule that reads the information in DNA, so our bodies can produce a complete functional protein. Envisagenic’s goal is to learn how to properly splice this RNA molecule so that they can determine why it is not producing the protein that it should so that those of us with SMA can either sustain the muscle that we already have, or better yet, why we are unable to build new muscle. Their database, SpliceCore, is the largest database to date with regards to RNA sequencing data. This video should be available around the first of July. Leave your comments below, and I’ll be more than happy to answer your questions.
Sounds great Michael. I look forward to hearing your perspective on this. Do you think this information is something all the big drug manufacturers will take into account: Biogen, AveXis, Cytokinetics, etc.?
Yes, I think Envisagenic’s splicing procedure will be something that all the pharmaceutical companies will have to address. If I’m not mistaken, I believe Envisagenics was suppose to be at the conference, but because of FDA regulations, since they were in their “moment of silence” period, they were only allowed to have a statement read outloud to those attending the Q&A session.
SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.